[HTML] sciencedirect.com

[HTML][HTML] Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer's disease

F Imam, S Mukhopadhyay, P Kothiyal, S Alshehri… - Saudi Pharmaceutical …, 2024 - Elsevier
Memory loss or dementia is a progressive disorder, and one of its common forms is
Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present …
相关文章
[HTML] nih.gov

[HTML][HTML] Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer's disease

F Imam, S Mukhopadhyay, P Kothiyal… - Saudi Pharmaceutical …, 2024 - ncbi.nlm.nih.gov
Memory loss or dementia is a progressive disorder, and one of its common forms is
Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present …

Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer's disease

F Imam, S Mukhopadhyay… - … journal: SPJ: the …, 2024 - pubmed.ncbi.nlm.nih.gov
Memory loss or dementia is a progressive disorder, and one of its common forms is
Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present …

Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer's disease

F Imam, S Mukhopadhyay, P Kothiyal… - Saudi Pharmaceutical …, 2024 - europepmc.org
Memory loss or dementia is a progressive disorder, and one of its common forms is
Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present …

Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer's disease.

F Imam, S Mukhopadhyay, P Kothiyal… - … Journal: SPJ: the …, 2024 - europepmc.org
Memory loss or dementia is a progressive disorder, and one of its common forms is
Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present …